ERBB2 and invasive carcinoma: Thus, patients with residual invasive carcinoma after neoadjuvant chemotherapy will be offered capecitabine as an adjuvant in the TN population as highlighted in the CREATE-X trial [30], or trastuzumab emtansine (TDM1) in HER2+ patients as shown in phase 3 Katherine study [31].